The Probiotic Preparation, VSL#3 Induces Remission in Patients With Mild-to-Moderately Active Ulcerative Colitis

Clinical Gastroenterology and Hepatology

Volumn 7, Issue 11, 2009, Pages

  Sood, Ajit ^a   Midha, Vandana ^a   Makharia, Govind K ^b   Ahuja, Vineet ^b   Singal, Dinesh ^c   Goswami, Pooja ^b   Tandon, Rakesh K ^c  

^a DAYANAND MEDICAL COLLEGE AND HOSPITAL   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^c Pushpawati Singhania Research Institute   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; MESALAZINE; PLACEBO; VSL3;

ABDOMINAL DISCOMFORT; ADULT; ARTICLE; BACTERIAL STRAIN; BIFIDOBACTERIACEAE; BLOATING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; LACTOBACILLUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCORING SYSTEM; STREPTOCOCCUS THERMOPHILUS; TREATMENT RESPONSE; ULCERATIVE COLITIS;

EID: 72049119604     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2009.07.016     Document Type: Article

References (35)

1. Sartor R.B. Intestinal microflora in human and experimental inflammatory bowel disease. Curr Opin Gastroenterol 17 (2001) 324-330
2. Sellon R.K., Tonkonogy S., Schultz M., et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 66 (1998) 5224-5231
3. Sartor R.B. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 126 (2004) 1620-1633
4. Madsen K.L., Doyle J.S., Jewell L.D., et al. Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. Gastroenterology 116 (1999) 1107-1114
5. Swidsinski A., Ladhoff A., Pernthaler A., et al. Mucosal flora in inflammatory bowel disease. Gastroenterology 122 (2002) 44-54
6. Fedorak R.N., and Dieleman L.A. Probiotics in the treatment of human inflammatory bowel diseases: update 2008. J Clin Gastroenterol 42 Suppl 2 (2008) S97-S103
7. Baumgart D.C., and Sandborn W.J. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369 (2007) 1641-1657
8. Hart A.L., Lammers K., Brigidi P., et al. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 53 (2004) 1602-1609
9. Petrof E.O., Kojima K., Ropeleski M.J., et al. Probiotics inhibit nuclear factor-kappaB and induce heat shock proteins in colonic epithelial cells through proteasome inhibition. Gastroenterology 127 (2004) 1474-1487
10. Fuller R. Probiotics in man and animals. J Appl Bacteriol 66 (1989) 365-378
11. Chapman T.M., Plosker G.L., and Figgitt D.P. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases. Drugs 66 (2006) 1371-1387
12. Rembacken B.J., Snelling A.M., Hawkey P.M., et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354 (1999) 635-639
13. Gionchetti P., Rizzello F., Venturi A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119 (2000) 305-309
14. Gionchetti P., Rizzello F., Helwig U., et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124 (2003) 1202-1209
15. Kruis W., Schutz E., Fric P., et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther 11 (1997) 853-858
16. Kruis W., Fric P., Pokrotnieks J., et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53 (2004) 1617-1623
17. Guslandi M., Giollo P., and Testoni P.A. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol 15 (2003) 697-698
18. Ishikawa H., Akedo I., Umesaki Y., et al. Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis. J Am Coll Nutr 22 (2003) 56-63
19. Furrie E., Macfarlane S., Kennedy A., et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial. Gut 54 (2005) 242-249
20. Kato K., Mizuno S., Umesaki Y., et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment Pharmacol Ther 20 (2004) 1133-1141
21. Bibiloni R., Fedorak R.N., Tannock G.W., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100 (2005) 1539-1546
22. Tursi A., Brandimarte G., Giorgetti G.M., et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit 10 (2004) PI126-PI131
23. Mallon P., McKay D., Kirk S., et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 4 (2007) CD005573
24. Miele E., Pascarella F., Giannetti E., et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104 (2009) 437-443
25. Huynh H.Q., Debruyn J., Guan L., et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis 15 (2009) 760-768
26. Rizzello F., Gionchetti P., Venturi A., et al. Review article: monitoring activity in ulcerative colitis. Aliment Pharmacol Ther 16 Suppl 4 (2002) 3-6
27. Greenfield S.M., Punchard N.A., Teare J.P., et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther 7 (1993) 369-383
28. Wallace J.L., Vergnolle N., Muscara M.N., et al. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology 117 (1999) 557-566
29. Schlee M., Harder J., Koten B., et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 151 (2008) 528-535
30. Madsen K., Cornish A., Soper P., et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 121 (2001) 580-591
31. Otte J.M., and Podolsky D.K. Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 286 (2004) G613-G626
32. Lammers K.M., Brigidi P., Vitali B., et al. Immunomodulatory effects of probiotic bacteria DNA: IL-1 and IL-10 response in human peripheral blood mononuclear cells. FEMS Immunol Med Microbiol 38 (2003) 165-172
33. Shibolet O., Karmeli F., Eliakim R., et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis 8 (2002) 399-406
34. Rachmilewitz D., Karmeli F., Takabayashi K., et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122 (2002) 1428-1441
35. Borriello S.P., Hammes W.P., Holzapfel W., et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis 36 (2003) 775-780